Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT04530227
Phase
PHASE2
Status
Unknown

Conditions

  • Early Stage Non-small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to assess the efficacy and safety of Camrelizumab plus chemotherapy in the treatment of adult participants with medically inoperable Stage I or IIA non-small cell lung cancer (NSCLC).

Key Dates

Start date
Sep 25, 2020
Status verified
Aug 2020
Primary completion
Jun 30, 2025
Completion
Dec 31, 2025

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab combined with chemotherapy
    Participants receive camrelizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 18 cycles PLUS Investigator's choice of chemotherapy. Interventions: Biological: Camrelizumab

Primary Outcome Measure

Progression-free Survival (PFS) [ Time Frame: up to approximately 3 years ]

Central Contacts

Related Studies